- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02304042
Carbetocin Versus Oxytocin in the Prevention of Post Partum Haemorrhage (PPH) in Women Delivered Vaginally With at Least 2 Risk Factors for Atonic PPH: A Randomised Controlled Trial (PPH)
Study Overview
Detailed Description
Obstetric haemorrhage remains one of the major causes of maternal death in both developed and developing countries (1). Postpartum haemorrhage (PPH) is defined as a blood loss >500 ml more of blood from the genital tract within 24 hours of the birth of a baby. PPH can be minor (500-1000 ml) or major (more than 1000 ml). The most frequent cause of PPH is uterine atony, contributing up to 80 % of the PPH cases.
Risk factors of atonic PPH include multiple pregnancy, placenta previa, previous PPH, body mass index (BMI) >30, prolonged labour, fetal macrosomia>4kg and primipara> 40 years.
Oxytocin is currently the uterotonic of first choice. It has proven to decrease the incidence of PPH by 40 % and has a rapid onset of action and a good safety profile. A disadvantage of oxytocin is its short half-life of 4-10 min, regularly requiring a continuous intravenous infusion or repeated intramuscular injections.
Carbetocin is a long-acting oxytocin analogue indicated for the prevention of uterine atony after child birth by CS under epidural or spinal anaesthesia. Carbetocin has a rapid onset of action (within 1-2 min) and a prolonged duration of action (approximately 1 h) because of sustained uterine response with contractions of higher amplitude and frequency. Its safety profile is comparable to that of oxytocin.
The study will be conducted in Cairo university hospitals and BeniSuef university hospitals. All patients with at least 2 risk factors for developing atonic PPH will be approached in the antenatal clinic or early in labour if appropriate. Risk factors include previous PPH, BMI>35, multiple pregnancy, prolonged labour >12 hours, fetal macrosomia>4kg and induction of labour. Women will be invited to participate in the study, the invitation will include a clear full explanation of the study. Only patients signing informed written consents will participate in the study.
250 women will be randomly divided into 2 equal groups using computer generated random numbers. Group 1 will receive Carbetocin 100 µgm (Pabal® Ferring, UK) and group 2 will receive oxytocin 5IU (Syntocinon®, Novartis, Switzerland). Both drugs will be diluted in 10ml saline and will be given by the slowly intravenously after delivery of the anterior shoulder. We will not include a control group for ethical reasons.
The uterine tone and amount of bleeding will be noted and the need for further uterotonic agents will be determined 2 minutes after giving the drug. Blood loss will be estimated through weighing the swabs and using pictorial charts. Blood haemoglobin will be assessed 24 hours after delivery.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
BeniSuef, Egypt
- BeniSuef University hospitals
-
Cairo, Egypt
- Cairo University hospitals
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women with at least 2 risk factors for developing PPH. Risk factors include previous PPH, BMI>35, multiple pregnancy, prolonged labour >12 hours, ultrasound estimated fetal weight>4kg and induction of labour.
Exclusion Criteria:
- Gestational age <37 weeks
- Placenta previa
- Hypertension.
- Preeclampsia.
- Cardiac, renal or liver diseases
- Known hypersensitivity to Carbetocin.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Carbetocin
125 women will receive carbetocin after delivery of the anterior shoulder.
The drug will be diluted in 10ml saline and will be given by the slowly intravenously after delivery of the anterior shoulder
|
Carbetocin will be given slowly iv after delivery of the anterior shoulder.
|
Active Comparator: Oxytocin
125 women will receive carbetocin oxytocin after delivery of the anterior shoulder.
The drug will be diluted in 10ml saline and will be given by the slowly intravenously after delivery of the anterior shoulder
|
Oxytocin will be given slowly iv after delivery of the anterior shoulder.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Need for other uterotonics
Time Frame: 2 minutes after giving the drug
|
After giving the drug, the uterine tone will be felt and amount of bleeding will be estimated.
|
2 minutes after giving the drug
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bleeding>500ml
Time Frame: 2 minutes after giving the drug.
|
The amount of bleeding will be estimated 2 minutes after giving the drug.
|
2 minutes after giving the drug.
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Winter C, Macfarlane A, Deneux-Tharaux C, Zhang WH, Alexander S, Brocklehurst P, Bouvier-Colle MH, Prendiville W, Cararach V, van Roosmalen J, Berbik I, Klein M, Ayres-de-Campos D, Erkkola R, Chiechi LM, Langhoff-Roos J, Stray-Pedersen B, Troeger C. Variations in policies for management of the third stage of labour and the immediate management of postpartum haemorrhage in Europe. BJOG. 2007 Jul;114(7):845-54. doi: 10.1111/j.1471-0528.2007.01377.x.
- Moertl MG, Friedrich S, Kraschl J, Wadsack C, Lang U, Schlembach D. Haemodynamic effects of carbetocin and oxytocin given as intravenous bolus on women undergoing caesarean delivery: a randomised trial. BJOG. 2011 Oct;118(11):1349-56. doi: 10.1111/j.1471-0528.2011.03022.x. Epub 2011 Jun 14. Erratum In: BJOG. 2011 Nov;118(12):1549.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PPH 2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Delivery
-
Rambam Health Care CampusRecruitingCesarean Delivery Affecting Fetus | Delivery ComplicationIsrael
-
Alzahraa Ismail Ragheb GodaUnknownDelivery ,Complications,Maternal | Delivery,Complication,FetalEgypt
-
The Reading Hospital and Medical CenterRecruitingPregnancy Related | Cesarean Delivery Affecting Fetus | Delivery ComplicationUnited States
-
Charite University, Berlin, GermanyCompletedCesarean Section Complications | Cesarean Delivery Affecting Newborn | Cesarean Delivery Affecting FetusGermany
-
Oslo University HospitalVestre Viken Hospital Trust; Helse Stavanger HF; Haukeland University Hospital; Sorlandet Hospital HF and other collaboratorsCompletedDelivery Complication | Induced; Birth | Indications for Care in Pregnancy; Labor; and DeliveryNorway
-
Kayseri Education and Research HospitalCompletedInflammation | Delivery | Cesarean Delivery
-
Centre Hospitalier René DubosCompleted
-
University Hospital, CaenCompleted
-
Hadassah Medical OrganizationUnknown
Clinical Trials on Carbetocin
-
Ciusss de L'Est de l'Île de MontréalCompletedCesarean Section Complications | Hemodynamic InstabilityCanada
-
University Hospital, Basel, SwitzerlandObstetric Anaesthetists' Association United KingdomCompletedAnesthesia; Reaction | Complications; Cesarean SectionSwitzerland
-
Levo Therapeutics, Inc.CompletedPrader-Willi SyndromeUnited States, Canada, Australia
-
University of British ColumbiaEdwards LifesciencesCompletedPregnancy | Effect of Carbetocin on Cardiovascular SystemCanada
-
Bezmialem Vakif UniversityCompleted
-
Cairo UniversityCompletedAbdominal MyomectomyEgypt
-
Cairo UniversityRecruitingPostpartum HemorrhageEgypt
-
Sohag UniversityAl-Azhar UniversityUnknownPostpartum HemorrhageEgypt
-
National University Hospital, SingaporeNational Healthcare Group, SingaporeCompleted
-
Cairo UniversityCompletedPost Partum Hemorrhage | Obesity, MaternalEgypt